Newsfeeds Archive - Page 2 of 4

3 minute read

Scholar Rock To Present Clinical And Biomarker Data From The Phase 1 DRAGON Trial At The SITC 38th Annual Meeting

October 19, 8:18 AM

Poster presentations to include safety, efficacy, and biomarker data from Part A and B of the DRAGON trial in patients with advanced solid tumors treated with SRK-181Scholar Rock (NASDAQ:SRRK), a Phase 3 clinical-stage

SRRK

2 minute read

Over $15M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying

By Lisa Levin

October 17, 7:05 AM

Although U.S. stocks closed higher on Monday, there were a few notable insider trades.

ASAN

4 minute read

Why InMode Shares Are Trading Lower By 20%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session

By Lisa Levin

October 12, 12:55 PM

Gainers

ACXP

2 minute read

Domino’s, Walgreens, Fastenal And Other Big Stocks Moving Higher On Thursday

By Lisa Levin

October 12, 11:52 AM

U.S. stocks traded mixed, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session.

AMAM

4 minute read

Why CalAmp Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

October 6, 1:59 PM

Gainers

AEHR

2 minute read

NuScale Power, Stagwell And Other Big Stocks Moving Higher On Friday

By Lisa Levin

October 6, 12:10 PM

U.S. stocks traded higher, with the Nasdaq Composite gaining around 50 points on Friday. Here are some big stocks recording gains in Friday's session.

AMRX

3 minute read

Scholar Rock Announces Completion Of Enrollment For The Phase 3 SAPPHIRE Trial; Topline Data From Phase 3 Trial Expected In Q4 2024

By Benzinga Newsdesk

September 19, 8:03 AM

Topline data from Phase 3 trial expected in Q4 2024Company to present encore 36-month efficacy, safety, and patient-reported outcomes data from the Phase 2 TOPAZ trial extension at the 2023 World Muscle Society (WMS)

SRRK

2 minute read

Scholar Rock’s New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial And Sustained Improvement Of Motor Function In Phase 2 TOPAZ Trial Patients With Nonambulatory Spinal Muscular Atrophy

By Happy Mohamed

June 30, 11:01 AM

- Improvements in patient-reported outcomes consistent with gains in motor function scores - Safety profile at 36 months consistent with previous reports with no new safety findings; more than 90 percent of nonambulatory patients remained on study

SRRK

4 minute read

Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

June 26, 12:31 PM

Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy.

ATUS